Camptothecins are potent DNA/topoisomerase-I interacting agents and combine the merits of both cytotoxic and molecularly targeted agents (1) (2) (3) . Their potency is controlled by their α-hydroxy-δ-lactone pharmacophore, which hydrolyses to the open ring or carboxylate form in a pH dependent but reversible manner. Although both the lactone and carboxylate forms have been shown to interact with the DNA/Topoisomerase-I complex, the lactone moiety is considered the active one (1, 3, 4) . This may be attributed to the higher lipophilicity of the lactone form that could facilitate cell penetration compared with the charged carboxylate (5) . In addition to the intrinsic hydrolysis rate of each analogue, the carboxylate binds human serum albumin with high affinity and facilitates an equilibrium shift toward hydrolysis, thus further compromising the lactone form by creating sink conditions (6) (7) (8) (9) .
Given that camptothecin pharmacokinetics (PK) present a significant challenge to achieving lactone exposure, there has been a tremendous effort to create novel analogues with improved stability and potency (10) . One such effort was initiated by the research groups of Drs. Thomas Burke and Dennis Curran that successfully achieved lactone stabilization by introducing substituents that promote lipid bilayer partitioning (hence protecting the drug from hydrolysis) and minimized albumin binding (7, 9, 11) . Several silatecans and homosilatecans were synthesized and tested for their blood stability and potency (12) (13) (14) (15) . Among those, 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67), also known as DB-67, emerged as the most blood-stable and potent analogue and was chosen for further preclinical and clinical development (12, 15, 16) .
We initiated this phase I trial to determine the maximum tolerated dosage (MTD) and describe the dose limiting toxicities (DLT) of i.v. AR-67 administered once daily for 5 days of an every-21-day schedule to adults with refractory and metastatic solid tumors. In addition, we evaluated antitumor activity, evaluated the PK, and explored the correlations between AR-67 exposure and toxicity.
Materials and Methods
Patient eligibility. Patients (ages >18 y) with refractory solid malignancies were eligible if their disease was metastatic or unresectable, and standard curative or palliative measures no longer existed or were no longer effective. Other eligibility requirements included Eastern Cooperative Group performance status of ≤2 and adequate hematologic [leukocytes of >3,000/μL, absolute neutrophil count (ANC) of >1,500/μL, platelet count of >100,000/μL], hepatic, and renal function. Objective measurable disease was not required. No prior chemotherapy, molecularly targeted agents, or radiation therapy was allowed within 2 wk (6 wk for mitomycin C or nitrosoureas), and no major surgery was allowed within 3 wk; all therapy-related toxicity should have resolved to less than grade 1. Prior camptothecin therapy was allowed, but patients with allergic reactions attributed to compounds of similar chemical or biological composition to AR-67, or subjects with prior grade 3 or 4 anaphylactic reaction to any product formulated with cremophor (i.e., paclitaxel) were excluded. Patients with known brain metastases that had been treated and were clinically stable were eligible for this clinical trial.
Other exclusions included subjects with uncontrolled intercurrent illness that would limit study compliance, HIV disease, QTc prolongation over 450 ms, evidence of ongoing and significant consumptive coagulopathy, or pregnant or nursing females.
Study drug. AR-67 was supplied by the National Cancer Institute (Rapid Access to Intervention Development program) in vials that contained 10 mg/2 mL in cremophor ethanol diluent. After reconstitution with 5% dextrose for injection in non-polyvinyl chloride bags (0.05-0.5 mg/mL), the drug was administered at a constant rate over 1 h into a free-flowing i.v. line (nonpolyvinyl chloride tubing) of 5% dextrose through a standard infusion pump. The drug was given within 4 h of reconstitution to ensure lactone stability.
Study treatments and dose escalation. Because it is established that 25% to 30% of those receiving cremophor-formulated compounds will experience grade 3 or 4 allergic infusion reactions (17) , all patients were premedicated to prevent potential cremophor toxicities as follows: 20 mg dexamethasone orally, 12 h before the first dose of AR-67 and 30 min before each dose on days 1 to 5, 8 mg ondansetron p.o., 10 mg loratidine p.o., 20 mg famotidine p.o., and 25 mg diphenhydramine p.o. Institutional equivalents were allowed. Investigators could reduce the dose of dexamethasone if no allergic reactions were noted in the previous cycle.
The phase I starting dose was 1.67 mg/m 2 /d, i.v., five times daily. The first patient (prostate cancer) at dose level 1 developed a grade 4 thrombocytopenia and consumptive coagulopathy, and his dose was reduced to level −1 (1.2 mg/m 2 ) for safety. Ultimately, toxicities were attributed to a disease progression with extensive bone metastasis and myelophthisic marrow changes, and consumptive coagulopathy. This phase I trial was designed to have an accelerated dose escalation followed by a modified Fibonacci design when certain parameters were met. Accordingly, after two subjects developed grade 2 toxicity early in the study, the study reverted to a modified Fibonacci design, as required by protocol. After eight more subjects were accrued and showed no grade 2 or greater toxicities, a secondary accelerated phase design was proposed and approved by the Institutional Review Board to expose the minimal number of subjects to potentially subtherapeutic dosage levels. Two dosage level escalations occurred during this secondary accelerated phase (at 4.5 and 6.3 mg/m 2 ), with subsequent expansion to a modified Fibonacci design at dosage level 5.5 (7.5 mg/m 2 ). All dosage levels are described in Table 1 .
Assessments, follow-up, and monitoring. Toxicities were defined using the National Cancer Institute Common Toxicity Criteria 3.0 (CTCAE 3.0). The toxicity of a given AR-67 dosage level was considered a DLT if any of the following were observed during cycle 1: (a) any grade 5 toxicity; (b) ANC of <500/μL for longer than 7 d or associated with fever or infection of any duration; (c) platelet of <25,000/μL of any duration; and (d) grade 3 or 4 nonhematopoietic toxicity according to the CTCAE version 3.0
Translational Relevance
Topoisomerase I interacting agents have shown antineoplastic activity that is closely associated with the stability of their α-hydroxy-δ-lactone pharmacophore. 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (AR-67) is a novel third generation camptothecin analogue with increased lipophilicity and blood stability, relative to the clinically approved analogues topotecan and irinotecan. This phase I study was conducted to determine the maximum tolerated dose, dose limiting toxicities, and pharmacokinetics of AR-67 given daily for 5 days during a 21-day cycle to patients with advanced solid tumors. Four patients experienced stable disease and one patient had prolonged partial response (>16 months), indicating preliminary evidence of antitumor activity. Hematologic toxicities were manageable and notably none of the patients experienced diarrhea. AR-67 exhibited increased blood stability, and compared with other lipophilic investigational analogues, it did not seem to accumulate in plasma with repeat dosing. AR-67 warrants further evaluation to assess its efficacy alone or in combination with other agents.
with the exception of grade 3 nausea and/or vomiting, grade 3 diarrhea of <3 d after treatment with loperamide, or grade 3 fever (with or without neutropenia). The recommended phase II dose and the MTD were defined as the dosage level below the dosage that induced a DLT in two or more patients during cycle 1. Routine use of colony-stimulating factors were not permitted during cycle one. Treatment was resumed once the ANC had recovered to ≥1,500/μL and a platelet of >100,000/μL (measured within 1 d of treatment), and when resolution of all nonhematologic toxicity to less than grade 2. If these parameters were not met, therapy was delayed for up to 3 wk for recovery. AR-67 dosage reductions by one dosage level were made for any DLT, any grade 4 neutropenia or thrombocytopenia, or grade 3 or 4 nonhematologic toxicity in the previous cycle. A maximum of two dose reductions were allowed per subject and no dosage escalations were allowed. In the absence of treatment delays due to adverse events, treatment continued until one of the following occurred: disease progression, unacceptable adverse event(s), request of patient to withdraw from study, general or specific changes in the patient's condition that rendered further treatment unacceptable, or treatment delay of >3 wk. Tumor measurements were done by computer tomography scan or magnetic resonance imaging every two cycles of therapy. Disease was assessed according to the Response Evaluation Criteria in Solid Tumors (v1.0; ref. 18). Treatment was continued for six cycles in the absence of disease progression, provided that all toxicities remained acceptable and patients were willing to continue on study.
Pharmacokinetic and pharmacodynamic methods. Blood was collected from all patients in heparinized tubes at predose, 5, 45, 65 min, and 1.5, 2, 4, 6, 8, and 24 h after the start of infusion on days 1 and 4. Day 4 samples were collected to determine if repeat dosing of AR-67 would result in drug accumulation as previously noted with other third generation lipophilic camptothecin analogues (19) . AR-67 lactone and carboxylate concentrations were determined in plasma by a validated high-performance liquid chromatography method with fluorescence detection based on a previously published assay (20) . Plasma PK parameters were estimated by noncompartmental methods with WinNonlin (version 5.2; Pharsight). Clearance values were compared by the Wilcoxon signed-rank paired test to assess differences between days 1 and 4. Relationships between drug exposure and toxicity were explored using sigmoid E-max and logistic regression models (Graph-Pad Table 2 . Overall, 61 courses of AR-67 over nine dosage levels were delivered. One patient at dose level 1 received only 2 d of drug administration before progressive disease manifested by bowel obstruction that required hospitalization, and was removed from study. This subject was not evaluable for response, but was evaluable for toxicity.
Toxicity. DLTs were observed in five patients: two of two subjects at 12. Table 3 summarizes all CTCAE toxicities at least possibly related to AR-67. Common grade 3 and 4 toxicities included leukocytopenia (23%), thrombocytopenia (15.4%), fatigue (15.4%), neutropenia (11.5%), and anemia (11.5%). Notably, none of the patients experienced infusion-related allergic reactions or diarrhea.
Efficacy. The secondary end point of response per Response Evaluation Criteria in Solid Tumors v1.0 was evaluable in 22 subjects. One subject with squamous cell carcinoma of the lung received 10 cycles of therapy and had a prolonged partial response at dosage level 5.5. This response continues as of this writing, 7 months after cessation of therapy (see Supplementary Fig. S1 ). Four subjects had stable disease: one patient at dosage level 7 with duodenal cancer (82 days), two patients at dosage levels 5.5 and 6 with small cell lung cancer (refractory disease, 91 days; sensitive relapse, 112 days), and one patient with nonsmall cell lung cancer (NSCLC) at dose level 5.5 (74 days). Pharmacokinetics. This compound was designed to promote lactone stability in vivo with the presumption that high lactone stability would lead to improved efficacy. Our results show that in human plasma, the AR-67 lactone form accounts for 87.5% (±8.5%, SD) of the total AR-67 AUC (lactone + carboxylate). Summary PK parameters of total AR-67 at each dosage level and lactone AUCs are presented in Table 4 . Mean plasma concentrations for the MTD cohort are presented in Fig. 1A . The drug is eliminated with a biexponential profile and there is no evidence of accumulation on day 4. Greater than 80% of the total concentration is in the lactone form (Fig. 1B) at each time point. The values of the lactone and total AUC (Fig. 1C) were highly correlated (Spearman correlation: r = 0.99, P < 0.0001 and r = 0.99, P < 0.0001 for day 1 and 4, respectively). Given this strong correlation and the high lactone to total AR-67 ratio, further analysis was done based on the total AR-67 concentrations. Linear regression and correlation analysis showed that the increase in maximum concentration (C max ) (data not shown) and AUC were dose dependent, whereas clearance was constant. As shown in Fig. 1D , no correlation was observed between dosage and clearance, suggesting that clearance was constant across dosage levels. However, the mean clearance of total AR-67 increased 20% [P = 0.0031, Wilcoxon signed-rank two-tailed t test) from day 1 (14.5 ± 4.1 L/ h/m 2 , n = 26)] to day 4 (17.4 ± 5.2 L/h/m 2 , SD, n = 25). It should be noted that the noncompartmental analysis may slightly overestimate the clearance because the true C max may not have been captured by the 45-minute sample, which was collected during the infusion.
Pharmacodynamics. Given the high correlation and low variability in the lactone to total AR-67 ratio in all subjects, we used the total AR-67 PK parameters to explore relationship between exposure and toxicity. Total AR-67 exposure and the observed hematologic DLTs were examined using a sigmoid E-max model (Equation 1). Where E (d) is the effect as a function of AUC or dosage, H is the Research.
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Figure 2 depicts the relationship between dosage level (A) or AUC (B) and the percentage of decrease in ANC and platelets from baseline. The dosage level ED 50 of 6.1 [95% confidence interval (95% CI), 4.3-8.7] and 4.9 (95% CI, 3.2-7.6) mg/m 2 were estimated for the percentage of decrease in ANC and platelets, respectively. The estimated AUC ED 50 values were 323.6 (95% CI, 231.9-451.6) and 364.2 (95% CI, 249.4-531.9) h*ng/mL for ANC and platelets, respectively.
To determine the probability for the occurrence of each toxicity during cycle 1, we performed logistic regression (Equation 2), where P is the probability, X (values of 1 or 0) denotes the presence or absence, respectively, of toxicity determined by a nadir value below the respective lower limit set for ANC (<1,500/mm 3 ) and platelets (<100,000/mm 3 ), and α and β are model parameters (α representing the log-odds of toxicity occurrence when X = 0 and β is the increment in the log-odds of toxicity when X = 1). Furthermore, the parameter β describes the steepness of the s-shaped curved or the rate of change in probability with increasing drug exposure.
As depicted in Fig. 2C , during cycle 1, the occurrence of neutropenia was more likely than thrombocytopenia at exposures, resulting from the MTD dosage level. Strong correlations could also be shown between exposure and nadir values of ANC and platelets (see Supplementary  Fig. S2 ). This analysis shows that the correlations were similar when considering exposure in terms of AUC and dosage level (mg/m 2 ). Similar correlations were also observed with leucopenia and the probability for observing leucopenia was similar to that for neutropenia (data not shown). At the MTD level, ANC and platelet nadir levels were observed on days 10 to 14 during cycle 1 but patients recovered before day 22 (day 1 of cycle 2).
Discussion
AR-67 administered daily for 5 days of an every-21-day cycle was well tolerated in this study. DLTs were thrombocytopenia, febrile neutropenia, and fatigue, and the MTD was defined as 7.5 mg/m 2 /d. Notably, no diarrhea or allergic infusional reactions occurred in the 26 people exposed to this compound. At the recommended phase II dose of 7.5 mg/m 2 /d (n = 7), the regimen produced only modest and manageable side effects. Although fatigue and hematologic toxicities are hallmarks of camptothecins, the lack of diarrhea seen in the present trial is notable compared with the other drugs of this class, particularly irinotecan. Interestingly, although AR-67 is lipophilic and shares some structural characteristics with the active metabolite of irinotecan (i.e., SN-38), it does not undergo UGT1A1-mediated glucuronidation, but is extensively metabolized by UGT1A8, which is primarily expressed in the gastrointestinal tract (21, 22) . This may partly explain the lack of diarrhea observed in this study. Complete studies related to the metabolism and transport pathways of this compound are under way and will be presented elsewhere.
Pharmacokinetic studies showed that 87.5% (±8.5%) of the drug is in the lactone form. This represents a significant improvement in the effective drug delivery from other clinically approved camptothecins with reported lactone AUC ratios of 30% to 76% for irinotecan and irinotecanderived SN-38 (23) (24) (25) , and for topotecan (26) . With respect to third generation analogues, the AR-67 lactone ratio is lower than the reported values for gimatecan and karenitecin, both in early clinical trials, which exist in plasma as 90% to 98% (19, 27) and approximately 90% to 95% (28, 29) in the lactone form, respectively. However, the AR-67 elimination half-life (∼1.4 hours) may explain the lack of accumulation observed with gimatecan and karenitecin, which have documented half-lives of 77 and 15 hours, respectively (27) (28) (29) . Interestingly, despite their long half-lives, these analogues have not proven to be more effective than the clinically approved camptothecins, which exhibit shorter half-lives. Thus, the prolonged exposures required for efficacy in rapidly growing preclinical models are not necessarily important for improved clinical efficacy.
AR-67 clearance is linear and correlates with hematologic toxicity. Interestingly, AR-67 clearance increased on day 4 of cycle 1, suggesting that this may be due to dexamethasone cotreatment inducing CYP3A4 activity. This is consistent with our in vitro data showing that AR-67 is a substrate for CYP3A4 and with previous clinical evidence showing that dexamethasone treatment for 5 days induces CYP3A4 activity (21, 30) . However, CYP3A4 induction was highly variable in that study (30) compared with our data that shows a consistent ∼20% decrease in AUC between days 1 and 4 in all patients. Thus, it is possible that the drug is also inducing its own metabolism to some extent.
The use of the cremophor-ethanol excipient is associated with hypersensitivity reactions and has the potential to cause nonlinear PK (17, 31) . However, the amount of cremophor at the MTD is less that 4% of that administered to a patient receiving a typical paclitaxel dose of 200 mg/m 2 , and no patient exhibited hypersensitivity reactions. Nonetheless, patients treated in upcoming phase II studies will continue to receive prophylactic premedication to prevent potential hypersensitivity reactions.
The partial response seen in NSCLC is notable because of the rapid tumor regression shown by the computer tomography scan (see Supplementary Fig. S1 ). This subject continued to benefit, despite two dose reductions for a total of 10 cycles, and ultimately stopped treatment due to grade 3 fatigue. The partial response was ongoing 7 months after cessation of therapy. In addition, stable disease was noted in two patients with small cell lung cancer (refractory and sensitive relapse for over 3 months) and in one patient each with NSCLC and duodenal cancer. Camptothecins as a class have been proven effective in each of these cancer types, and further exploration of AR-67 in these groups is warranted (10) .
In conclusion, AR-67 given daily for 5 days in an every-21-day cycle is well tolerated, with acceptable myelosuppression and fatigue as DLTs. At the MTD, toxicities were manageable and no diarrhea or hypersensitivity reactions were seen. Critically important was the demonstration of high lactone stability (∼87.5% of total AR-67) in human plasma. Interestingly, a confirmed partial response was noted in a patient with NSCLC, who remained on therapy for 10 cycles. We also showed linear PK and correlation of AUC and dosage with toxicity. Further clinical testing of AR-67 is warranted and ongoing. 
